Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06

International Journal of Radiation Oncology Biology Physics

Volumn 40, Issue 4, 1998, Pages 765-768

  Hanks, Gerald E ^a   Buzydlowski, Jan ^b   Sause, William T ^c   Emami, Bahman ^d   Rubin, Philip ^e   Parsons, John A ^f   Russell, Anthony H ^g   Byhardt, Roger W ^h   Earle, John D ⁱ   Pilepich, Miljenko V ^j  

^a FOX CHASE CANCER CENTER   (United States)

^b AMERICAN COLLEGE OF RADIOLOGY   (United States)

^c LDS HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f University Health Center   (United States)

^g Mercy General Hospital   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ MAYO CLINIC   (United States)

^j Catherine McAuley Health Center   (United States)

more..

Author keywords

10 year outcomes; Node positive prostate cancer; Radiation therapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL TIME; TREATMENT OUTCOME;

DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031953899     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00921-8     Document Type: Article

References (19)

1. Pilepich M. V., Krall J. M., Sause W. T., Johnson R. J., Russ H. H., Hanks G. E., Perez C. A., Zinninger M., Martz K. L. Prognostic factors in carcinoma of the prostate analysis of RTOG 75-06 . Int. J. Radiat. Oncol. Biol. Phys. 13:1987;339-349.
2. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Statist. Assoc. 53:1958;447-457.
3. Cox D. R., Oakes D. Analysis of survival data. 1984;Chapman and Hall, London.
4. Bagshaw M. A. Radiotherapeutic treatment of prostatic carcinoma with pelvic node involvement. Urol. Clin. North Am. 11:1984;297-304.
5. Lawton C. A., Cox J. D., Glisch C., Murray K. J., Byhardt R. W., Wilson J. F. Is long-term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate? Cancer. 69:1992;2761-2766.
6. deKernion J. B., Neuwirth H., Stein A., Dorey F., Stenzl A., Hannah J., Blyth B. Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J. Urol. 144:1990;700-703.
7. Wiegel T., Bressel M. Influence of the extent of nodal involvement on the outcome in stage D1 prostate cancer. Radiat. Oncol. Invest. 2:1994;144-151.
8. Lee R. J., Sause W. T. Surgically staged patients with prostatic carcinoma treated with definitive radiotherapy - 15 year results. Urology. 43:1994;640-644.
9. Steinberg G. D., Epstein J. I., Piantadosi S., Walsh P. C. Management of stage D1 adenocarcinoma of the prostate the Johns Hopkins experience 1974 to 1987 . J. Urol. 144:1990;1425-1432.
10. Lawton C. A., Winter K., Byhardt R., Sause W. T., Hanks G. E., Russell A. H., Rotman M., Porter A., McGowan D. G., DelRowe J. D., Pilepich M. V. Androgen suppression plus radiation vs. radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial RTOG 85-31) Radiation Therapy Oncology Group . Int. J. Radiat. Oncol. Biol. Phys. 38:1997;931-939.
11. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337:(5):1997;295-300.
12. Pilepich M. V., Caplan R., Byhardt R. W., Lawton C. A., Gallagher M. J., Mesic J. B., Hanks G. E., Coughlin C. T., Porter A. Phase III trial of androgen suppression using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy - Report of RTOG 85-31. J. Clin. Oncol. 15:1997;1013-1021.
13. Pilepich M. V., Caplan R., Byhardt R. W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy report of Radiation Therapy Oncology Group Protocol 85-31 . J. Clin. Oncol. 15:1997;1013-1021.
14. Sands M. E., Pollack A., Zagars G. K. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. Int. J. Radiat. Oncol. Biol. Phys. 31:1995;13-19.
15. Whittington R., Malkowicz S. B., Barnes M. M., Broderick G. A., Van Arsdalen K., Dougherty M. J., Wein A. J. Combined hormonal and radiation therapy for lymph node-positive prostate cancer. Urology. 46:1995;213-219.
16. Partin A. W., Pearson J. D., Landis P. K., Carter H. B., Pound C. R., Clemens J. A. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 43:1994;649-659.
17. Pinover W. H., Hanlon A. L., Lee W. R., Kaplan E. J., Hanks G. E. Prostate cancer patients upstaged by imaging and treated with irradiation An outcome based analysis . Cancer. 77:1996;1334-1341.
18. Hanks G. E. The challenge of treating node positive prostate cancer an approach to resolving the questions . Cancer. 71:1993;1014-1018.
19. Hanks G. E., Hanlon A. L., Hudes G., Lee W. R., Suasin W., Schultheiss T. E. Patterns of failure analysis of patients with high pretreatment PSA treated by radiation therapy the need for improved systemic and locoregional treatment . J. Clin. Oncol. 14:1996;1093-1097.